Table 1.
Baseline characteristics according to randomized treatment arm
| Characteristic | Lower DNa (138 mmol/L) (n = 69) | Higher DNa (142 mmol/L) (n = 70) |
|---|---|---|
| Age, years | 61 ± 14 | 58 ± 15 |
| Male, n (%) | 43 (62) | 36 (51) |
| Black, n (%) | 21 (30) | 25 (36) |
| Diabetes, n (%) | 36 (52) | 39 (56) |
| Heart failure, n (%) | 29 (42) | 22 (31) |
| Catheter access, n (%) | 17 (25) | 14 (20) |
| Session length, min | 213 ± 31 | 208 ± 43 |
| Pre-HD SBP, mmHg | 135 ± 24 | 139 ± 24 |
| Anti-hypertensive use, n (%) | 42 (61) | 46 (66) |
| Pre-HD weight, kg | 80.4 ± 22.6 | 73.5 ± 20.9 |
| Serum sodium, mmol/L | 137 ± 4 | 137 ± 3 |
| Serum potassium, mmol/L | 4.7 ± 0.7 | 4.8 ± 0.7 |
| Serum albumin, g/dL | 3.2 ± 0.5 | 3.3 ± 0.5 |
| BUN, mg/dL | 49 ± 19 | 48 ± 16 |
| Hemoglobin, g/dL | 9.6 ± 1.5 | 9.6 ± 1.6 |
Values for continuous variables are given as mean ± standard deviation; values for categorical variables are given as count (percentage).
Values were missing for 62 patients for pre-HD weight, 89 patients for serum albumin, one patient for serum sodium, one patient for BUN and three patients for hemoglobin.